Welcome to our dedicated page for Janux Therapeutics SEC filings (Ticker: JANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Janux Therapeutics filings document a clinical-stage biopharmaceutical issuer developing tumor-activated immunotherapies through the TRACTr, TRACIr and ARM platforms. Recent 8-K reports furnish financial results and business updates covering clinical programs such as JANX007, JANX014, JANX011 and JANX008, as well as cash-position commentary and pipeline prioritization.
The company’s regulatory record also includes a material definitive agreement for the Bristol Myers Squibb collaboration, with license, development, commercialization, milestone and royalty terms. Proxy and governance filings document director elections, board-classification matters, executive compensation, pay-versus-performance disclosure and officer or director changes.
Janus Henderson Group plc reports beneficial ownership of 4,196,409 shares of Janux Therapeutics, Inc., representing 6.9% of the class as disclosed in an Amendment No. 5 to Schedule 13G/A.
The filing states the shares are held by multiple Janus Henderson asset managers exercising shared voting and shared dispositive power over 4,196,409 shares. The filing includes a disclaimeral statement about dividend and sale rights and lists subsidiary/exhibit references for Item 7.
Janux Therapeutics Vice President of Accounting Maria Dobek reported an open-market sale of 2,038 shares of Janux Therapeutics common stock at $14.17 per share on May 11, 2026. After this transaction, she continues to hold 32,270 shares directly.
State Street Corporation reports beneficial ownership of 4.1% of Janux Therapeutics common stock, representing 2,464,017 shares as of 03/31/2026. The filing lists shared voting power of 2,373,058 shares and shared dispositive power of 2,464,017 shares.
The schedule is a disclosure of institutional holdings under ownership-reporting rules and states the position is held for multiple advisory entities named in the filing. No change-in-control claim or acquisition transaction is asserted in this excerpt.
Janux Therapeutics reported a Q1 2026 net loss of $24.4 million, or $0.39 per share, as it continued investing heavily in R&D. The company generated its first collaboration revenue of $3.7 million, driven by a new agreement with Bristol-Myers Squibb.
Janux ended the quarter with $52.6 million in cash and cash equivalents and $904.6 million in short-term investments, supporting management’s view that funding is sufficient for at least 12 months. A $15.0 million upfront payment and a $35.0 million development milestone from BMS, plus $53.6 million of remaining performance obligations, provide significant non-dilutive financing for its clinical and preclinical immunotherapy programs.
Janux Therapeutics reported first quarter 2026 results, showing a net loss of $24.4 million or $0.39 per share, similar to the prior year. The company ended March 31, 2026 with a strong cash, cash equivalents and short-term investment balance of $956.4 million, supporting its clinical pipeline.
Collaboration revenue was $3.7 million, reflecting progress under partnered programs, including a $35 million milestone from its Bristol Myers Squibb collaboration. Research and development expenses rose modestly to $26.8 million, while general and administrative expenses increased to $11.1 million.
Janux advanced multiple candidates, with JANX007 continuing in a Phase 1b prostate cancer trial, clinical initiation of JANX014, and an ongoing Phase 1 study of JANX011 in healthy volunteers. The company discontinued development of JANX008 after completing Phase 1a and is prioritizing other programs.
FMR LLC filed an Amendment No. 5 to Schedule 13G/A reporting beneficial ownership of 2,535,723.63 shares of Janux Therapeutics Inc. (CUSIP 47103J105), representing 4.2% of the class as stated. The filing lists sole dispositive power of 2,535,723.63 shares and shows that one or more other persons may have rights to dividends or sale proceeds.
Signatures show filings executed by Richard Bourgelas on behalf of FMR LLC and Abigail P. Johnson, with a power of attorney dated April 13, 2026, and signature dates of 05/05/2026. The cover cites an as-of date of 03/31/2026.
Point72 affiliates and Steven A. Cohen report beneficial ownership of 3,069,759 shares of Janux Therapeutics common stock, representing 5.0% of the class as of April 28, 2026. The holdings are reported by Point72 Asset Management, L.P.; Point72 Capital Advisors, Inc.; and Steven A. Cohen under a joint filing agreement. The filing states the reporting persons own no shares directly and that shared voting and dispositive power over 3,069,759 shares is held through Point72 Associates, an investment fund managed by Point72 Asset Management.
Janux Therapeutics reported a Schedule 13G showing Point72 entities and Steven A. Cohen beneficially hold 5.0% of common stock.
The filing states Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen share voting and dispositive power over 3,069,759 shares as of April 28, 2026. The holders report no sole voting or dispositive power and identify a Joint Filing Agreement (Exhibit 99.1).
Janux Therapeutics, Inc. changed the board class designation of director Eric Dobmeier to rebalance its staggered board. On April 28, 2026, Dobmeier resigned as a Class III director, whose term would have run until the 2027 Annual Meeting of Stockholders, and was immediately reappointed as a Class II director, whose term runs until the 2026 Annual Meeting.
The company states his board service is treated as continuous for all purposes, including vesting and settlement of any outstanding equity awards and other non-employee director compensation. Dobmeier will continue serving on the Board’s Compensation Committee.